Related Experiment Video
Updated: Jun 20, 2026
08:13
Spatiotemporal Subcellular Manipulation of the Microtubule Cytoskeleton in the Living Preimplantation Mouse Embryo using Photostatins
Published on: November 30, 2021
Novel microtubule-targeting agents - the epothilones
Kit L Cheng1, Thomas Bradley, Daniel R Budman
1Monter Cancer Center, North Shore - LIJ Health Systems, Lake Success, New York, USA.
Biologics : Targets & Therapy
|August 27, 2009
Summary
Epothilones are novel antimicrotubule cancer drugs effective against resistant cell lines. While some cause diarrhea or myelosuppression, others like ixabepilone show promise for breast cancer treatment with manageable toxicities.
Area of Science:
- Oncology
- Pharmacology
- Medicinal Chemistry
Background:
- Epothilones represent a distinct class of antimicrotubule agents.
- Their unique chemical structures offer advantages for synthetic modification compared to taxanes.
- Six epothilones (patupilone, ixabepilone, BMS 310705, sagopilone, KOS-862, KOS-1584) have undergone preclinical and clinical investigation.
Purpose of the Study:
- To review the preclinical and clinical data of various epothilones.
- To compare their efficacy and toxicity profiles in cancer treatment.
- To highlight the clinical development and application of ixabepilone.
Main Methods:
- Review of in vitro studies demonstrating epothilone potency in diverse cancer cell lines.
- Analysis of Phase I clinical trial data to identify dose-limiting toxicities.
- Evaluation of published Phase II and III clinical data for ixabepilone.
Main Results:
- Epothilones exhibit enhanced cytotoxicity in taxane-sensitive and resistant cell lines due to poor p-glycoprotein interaction and high tubulin affinity.
- Dose-limiting toxicities vary by epothilone, including diarrhea, myelosuppression, and neurotoxicity.
- Ixabepilone demonstrates mature clinical results, regulatory approval for breast cancer, and combination therapy options.
Conclusions:
- Epothilones are a promising class of antimicrotubule agents with broad-spectrum activity.
- Understanding drug-specific toxicities is crucial for optimizing treatment regimens.
- Ixabepilone is an established treatment option for breast cancer, with ongoing research into combination therapies.
More Related Videos
Related Concept Videos
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:45Destabilization of Microtubules
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...